New and repurposed antibody-based drugs for COVID-19

ACROBiosystems is sponsoring this webinar!

Time: July 18th, Saturday, 9-10 pm, EST (July 19th, Sunday, 9-10 am, CST)

Speaker: Dr. Janice Reichert

Dr. Janice Reichert is an internationally-recognized expert in the development of antibody therapeutics. She is Executive Director of The Antibody Society, a non-profit association representing individuals and organizations that engage in antibody-related research or development. Dr. Reichert is also Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development, and Managing Director of Reichert Biotechnology Consulting LLC, a pharmaceutical business intelligence research firm. Dr. Reichert writes frequently on development trends for antibody therapeutics, including the annual “Antibodies to watch”articles published in mAbs, and she has presented her research results as an invited speaker at conferences held worldwide.

Webinar abstract:

The extraordinary scope and scale of the COVID-19 pandemic has elicited extraordinary responses world-wide. Organizations located across the globe mobilized teams to research the virus (SARS-CoV-2) and the disease (COVID-19) resulting from infection, and conduct clinical studies of drugs that were already marketed or in clinical development for other diseases with symptoms similar to those of COVID-19. As the disease spread, many organizations also began to research and develop new protein-based drugs (also called biologics), mostly monoclonal antibodies, that target the virus. The emergence of the new disease has substantially altered the landscape of antibody drug development due to the crucial and immediate need for effective anti- SARS-CoV-2 biologics for prophylaxis or treatment of COVID-19.

In this webinar, Dr. Janice Reichert (Executive Director, The Antibody Society) will discuss the ~ 130 biologics currently in the commercial pipeline for COVID-19, including over 50 repurposed biologics and over 80 new anti-SARS-CoV-2 biologics. Trends in late-stage clinical studies and approval of the repurposed biologics will be presented. Timelines for the start of clinical studies for new anti-SARS-CoV-2 antibody therapeutics and strategies for their rapid development will be discussed.